Changeflow GovPing Pharma & Drug Safety Probiotics to prevent cognitive dysfunction
Routine Notice Added Final

Probiotics to prevent cognitive dysfunction

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

What changed

USPTO issued Patent Grant US12593863B2 (Kind B2) on April 7, 2026, covering bacteria of the species Lacticaseibacillus paracasei for preventing or treating cognitive impairments in subjects. The patent also extends to cognitive impairments induced by sleep deprivation and/or insufficient sleep. Assignee is INTERNATIONAL N&H DENMARK APS, with a filing date of October 8, 2021, and Application No. 18248077.

This patent grant establishes intellectual property protection for the probiotic composition and its method of use. No immediate compliance actions are required from industry participants. Competitors developing similar probiotic formulations for cognitive health should review this patent for potential licensing needs or design-around considerations.

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Probiotics to prevent cognitive dysfunction

Grant US12593863B2 Kind: B2 Apr 07, 2026

Assignee

INTERNATIONAL N&H DENMARK APS

Inventors

Sile Griffin, Elaine Patterson, Markus Lehtinen

Abstract

This invention relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments in a subject in need thereof. This invention also relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments induced by sleep deprivation and/or insufficient sleep in a subject in need thereof.

CPC Classifications

A23L 33/135 A61P 25/28 A61K 2035/115

Filing Date

2021-10-08

Application No.

18248077

Claims

5

View original document →

Named provisions

Abstract Claims CPC Classifications

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12593863B2
Docket
18248077

Who this affects

Applies to
Drug manufacturers Healthcare providers Investors
Industry sector
3254 Pharmaceutical Manufacturing 3114 Food & Beverage Manufacturing 3254.1 Biotechnology
Activity scope
Patent Grant
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Intellectual Property
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!